个人简介

Dr. Christopher-Stine is currently Director of the Johns Hopkins Myositis Center. She is an Associate Professor of Medicine and Neurology. She also serves as one of the Johns Hopkins University School of Medicine College Advisors, and is a Board Member of the Johns Hopkins Institutional Review Board (IRB 5). Dr. Christopher-Stine graduated Cum Laude with a B.A. in chemistry from Franklin and Marshall College; was elected to Alpha Omega Alpha at Hahnemann University School of Medicine, where she received her MD degree, and she attained her Master of Public Health degree from the Johns Hopkins Bloomberg School of Public Health. Her internship and residency training were completed at MCP Hahnemann University, where she also served as Chief Resident, after which she pursued rheumatology fellowship training at Johns Hopkins. MD, Hahnemann University School of Medicine (1997)

研究领域

Dermatomyositis, Polymyositis, Inclusion Body Myositis, Inflammatory Myopathy, Necrotizing Myopathy, Statin Myopathy

Dr. Christopher-Stine’s primary research focus is clinical research pertaining to inflammatory myopathies – specifically describing unique phenotypes, novel therapeutic approaches, and novel disease subsets among patients with inflammatory myopathies who are part of the growing cohort of over 2000 patients evaluated clinically for confirmed or suspected muscle disease at the Myositis Center who agree to be part of the Johns Hopkins Myositis database. Dr. Christopher-Stine and her colleagues made the novel discovery of an autoimmune myopathy closely linked to statins. She has a continued interest in statins and their toxicities toward muscle, both as a direct muscle toxin as well as its contribution to autoimmune muscle injury. Dr. Christopher-Stine and her team are currently investigating several area of interest regarding the inflammatory myopathies. They are interested in cardiovascular complications in the inflammatory myopathies as well as the utilization of MRI imaging to help predict clinical phenotype, and they remain interested in predicting clinical outcomes. In addition, they are currently investigating the burden of calcinosis in adult dermatomyositis by patient self-report and then utilizing novel imaging modalities to examine the extent of calcinosis in these patients. In addition, as patient reported outcomes are growing increasingly important, especially in the context of clinical trials, they are an increasing focus of investigative efforts at the Myositis Center. Specifically, Dr. Christopher-Stine and her team are undertaking an international effort to determine the most appropriate patient-driven outcome measures in the inflammatory myopathies.

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Christopher-Stine L, Astor B Petri M, Fine D. Protein:Creatinine Ratio is A Reliable Measure of Proteinuria in Lupus Nephritis. J Rheumatol 2004;31:1557-9. Kalluri M, Sahn SA, Oddis CV, Gharib, Christopher-Stine, L, Danoff SK, Casciola-Rosen L, Hong G3, Dellaripa PF, Highland KB. Clinical profile of anti-PL-12 autoantibody: Cohort Study and Review of the Literature. Chest. 2009 Jun;135(6):1550-6. Valiyil R, Hong G, Casciola- Rosen L, Mammen AL, Christopher-Stine, L. Rituximab is an Effective Therapy for Myopathy Associated with Anti-Signal Recognition Particle Antibodies: A Case Series. Arthritis Care Res. 2010 Sep;62(9):1328-34 Christopher-Stine L, Hong G, Casciola-Rosen L, Corse A, Mammen AL. A novel autoantibody recognizing 200 and 100 kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010 Sep;62(9):2757-66 Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Casciola-Rosen LA. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011 Mar;63(3):713-21. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS).Ann Rheum Dis. 2011 May;70(5):760-5. Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, Zachary AA. Increased frequency of DRB1*11:01 in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Care Res. 2012 Aug;64(8):1233-7. Casciola-Rosen L, Hall JC, Christopher-Stine L, Mammen AL, Rosen A. Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. Clin Exp Rheumatol. 2012 Jul-Aug;30(4):548-53. Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, Lloyd TE Mammen AL. Antibody Levels Correlate with Creatine Kinase Levels and Strength in Anti-HMG-CoA Reductase-Associated Autoimmune Myopathy. Arthritis Rheum. 2012 Dec;64(12):4087-93. Alexanderson H, Del Grande M, Bingham III CO, Orbai AM, Sarver C, Clegg-Smith K, Lundberg IE, Song YW, Christopher-Stine L. Patient Reported outcomes and Adult Patients' disease experience in the Idiopathic Inflammatory Myopathies. A report from the OMERACT 11 Myositis Special Interest Group. J Rheumatol. 2014 Apr;41(4):792-8. ENMC Myositis Muscle Biopsy Study Group. 193rd ENMC International workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November – 2 December 2012, Naarden, The Netherlands. Neuromuscular Disorders 2013 (23): 945–951. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L.Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1-gamma. Arthritis Rheum. 2013 Nov;65(11):2954-62. Sharma K, Orbai AM, Desai D, Cingolani OH, Halushka MK, Christopher-Stine L, Mammen AL, Wu KC, Zakaria S. Brief Report: Antisynthetase Syndrome-Associated Myocarditis. J Card Fail. 2014 Jul 29 Johnson C, Connors GR, Oaks J, Han S, Truong A, Richardson B, Lechtzin N, Mammen AL, Casciola-Rosen L, Christopher-Stine L, Danoff SK. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med. 2014 Sep 18 Christopher-Stine L. Siedner M, Lin J, Haas M, Parekh H, Petri M, Fine DM. Renal Biopsy in Lupus Patients with Low Levels of Proteinuria. J Rheumatol. 2007 Feb;34(2):332-5. Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Oyoyemi K, Danoff SK, Christopher-Stine L. Anti melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013 Aug;65(8):1307-15. Lloyd TE* , Christopher-Stine L*, Penal-Fernandez I, Tiniakou E, Petri M, Baer A, , Danoff SK, Pak K, Casciola-Rosen L , and Mammen AL . Cytosolic 5'-nucleotidase 1A is a common target of circulating autoantibodies in several autoimmune diseases; Arthritis Rheum , 2015 Apr 17(Epub)